Related Experiment Video
Updated: Jul 16, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas
Irina V Lebedeva1, Ilyas Washington, Devanand Sarkar
1Department of Urology, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Abstract:
Effective therapies for most solid cancers, especially those that have progressed to metastasis, remain elusive because of inherent and acquired resistance of tumor cells to conventional treatments. Additionally, the effective therapeutic window for many protocols can be very narrow, frequently resulting in toxicity. The present study explores an anticancer strategy that effectively eliminates resistant cancer cells without exerting deleterious effects on normal cells. This approach employs melanoma differentiation-induced gene-7/interleukin-24 (mda-7/IL-24), a cancer-specific, apoptosis-inducing cytokine, in combination with nontoxic doses of a chemical compound from the endoperoxide class that decomposes in water generating singlet oxygen. This combinatorial regimen specifically induced in vitro apoptosis in prostate carcinoma cells, with innate resistance to chemotherapy or engineered resistance to mda-7/IL-24, as well as pancreatic carcinoma cells inherently resistant to any treatment modality, including mda-7/IL-24. Apoptosis induction correlated with increased cellular reactive oxygen species production and was prevented by general antioxidants, such as N-acetyl-l-cysteine or Tiron. Induction of apoptosis in combination-treated cancer cells correlated with a reduction in the antiapoptotic protein BCL-x(L). In contrast, both normal prostate and pancreatic epithelial cells were unaffected by the single or combination treatment. These provocative findings suggest that this combinatorial strategy might provide a platform for developing effective treatments for therapy-resistant cancers.
Insights
This study introduces a novel combination therapy using melanoma differentiation-induced gene-7/interleukin-24 (mda-7/IL-24) and singlet oxygen-generating compounds to effectively eliminate resistant cancer cells, including prostate and pancreatic carcinomas, without harming normal cells.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Therapeutic resistance in solid tumors, particularly metastatic cancers, limits treatment efficacy and narrow therapeutic windows often cause toxicity.
- Developing strategies to target resistant cancer cells without harming normal tissues is a critical unmet need in oncology.
Purpose of the Study:
- To investigate a novel combination therapy for resistant cancers using melanoma differentiation-induced gene-7/interleukin-24 (mda-7/IL-24) and endoperoxide-derived singlet oxygen.
- To evaluate the efficacy and specificity of this combination therapy against chemoresistant and mda-7/IL-24-resistant prostate and pancreatic cancer cells.
Main Methods:
- Utilized in vitro models of prostate and pancreatic carcinoma cells with inherent or engineered resistance.
- Administered a combination of mda-7/IL-24 and a nontoxic dose of an endoperoxide compound generating singlet oxygen.
- Assessed apoptosis induction, reactive oxygen species (ROS) production, and BCL-x(L) protein levels.
- Evaluated effects on normal prostate and pancreatic epithelial cells.
Main Results:
- The combination therapy specifically induced apoptosis in resistant prostate and pancreatic cancer cells.
- Apoptosis correlated with increased intracellular ROS and was mitigated by antioxidants.
- Treatment led to reduced levels of the antiapoptotic protein BCL-x(L).
- Normal epithelial cells remained unaffected by the combined treatment.
Conclusions:
- This mda-7/IL-24 and singlet oxygen-based combinatorial strategy effectively targets therapy-resistant cancers.
- The approach demonstrates specificity, sparing normal cells and offering a potential platform for new cancer treatments.
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...